Screener
Agios Pharmaceuticals AGIO Payments Associated With License Agreement
Payments Associated With License Agreement at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept agio:PaymentsAssociatedWithLicenseAgreement.
The source filing: Agios Pharmaceuticals’s 10-K, filed February 12, 2026. Open the filing →
- Filed
- Feb 12, 2026, 9:33 AM EST
- Fiscal year
- FY2025
- Accession
- 0001439222-26-000025
FAQ
- What is Agios Pharmaceuticals's payments associated with license agreement?
- Agios Pharmaceuticals (AGIO) reported payments associated with license agreement of $2.5M in Q4 2025.
- What does payments associated with license agreement mean?
- This represents the cash outflows made to acquire or secure rights to intellectual property, such as upfront payments for licensing agreements. It is a key indicator of the company's investment in external R&D and its commitment to expanding its product pipeline through partnerships. High levels of these payments signify an aggressive strategy to acquire external clinical assets.
Ask your AI about Agios Pharmaceuticals's payments associated with license agreement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude